Llwytho...
97. Competition Experiments for the Baloxavir-Resistant I38T Influenza A Mutant
BACKGROUND: Baloxavir marboxil (BXM), a cap-dependent endonuclease inhibitor, has been recently approved in the United States for the treatment of influenza infections. It is superior to oseltamivir for reducing the time of viral shedding but is reported to have a low barrier of resistance. We sough...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Open Forum Infect Dis |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Oxford University Press
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6808909/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.021 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|